Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  IDEXX Laboratories, Inc.    IDXX

Delayed Quote. Delayed  - 08/26 10:00:00 pm
110.15 USD   +0.22%
08/10 IDEXX LABORATOR : to Host 2016 Investor Day
08/08 IDEXX LABORATOR : to Host 2016 Investor Day
08/02 IDEXX LABORATOR : beats Street 2Q forecasts
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

IDEXX Laboratories : Announces Second Quarter Results

share with twitter share with LinkedIn share with facebook
share via e-mail
08/11/2016 | 08:24pm CEST

By a News Reporter-Staff News Editor at Investment Weekly News -- IDEXX Laboratories, Inc. (NASDAQ: IDXX) reported revenues for the second quarter of 2016 of $467 million, an increase of 13% compared to the prior year period. Organic revenue growth for the quarter was also 13%, supported by strong growth in the Companion Animal Group ("CAG") and Water segments.

Earnings per diluted share ("EPS") for the quarter was $0.74, an increase of 23% compared to the prior year period, while absorbing a negative $0.06 per share impact related to net changes in foreign exchange, resulting in constant currency EPS growth of 33%. The federal research and development tax credit, which benefited the current but not the prior year period, had a 2% favorable impact to EPS growth.

"We accelerated growth in the second quarter, further demonstrating the benefits of bringing our innovations to an attractive global market with an expanded commercial presence, including our move to a fully-direct sales strategy in the US companion animal market in 2015," said Jonathan Ayers, the Company's Chairman and Chief Executive Officer. "Our teams accomplished strong revenue gains across US and all international regions, with flow-through benefits that drove very strong profit results.

"We successfully launched SediVue Dx, our novel urine sediment point-of-care analyzer, with placements of 467 units in the quarter. This performance reflects the positive customer response to the streamlined workflow, high quality images, and consistency of results from the analyzer compared to the traditionally challenging manual process involving microscopic interpretation.

"We also achieved continued productivity gains in our commercial capabilities to drive another highly successful quarter for placements of Catalyst chemistry instruments, with placement of 1,334 systems, including 502 in North America. Impressively, an estimated 663 of our worldwide placements were to new and competitive accounts. Our global momentum in instrument placements drove accelerated 14% global reported and organic revenue gains in the recurring revenue of instrument consumables.

"Strong global commercial execution further drove the revenue growth of reference laboratory diagnostic and consulting services, with 15% reported and 14% organic gains, including strong double-digit growth in both the US and international regions. Reference lab revenue performance was supported by the growing appreciation of veterinarians around the world that IDEXX SDMA™ is a more reliable indicator of kidney related health than the traditional key kidney parameter, creatinine.

"We also continued to drive strong global growth in our Water business, with revenues up 11% reported and 12% organically in the quarter, expanding this base of highly profitable and durable recurring revenue.

"IDEXX innovations are resonating with customers, and with our expanded commercial capabilities, we are helping to transform the role of diagnostics in our markets. We clearly are firing on all cylinders.

"Given these strong results and related momentum, we are on track towards delivering on the consistent, long-term 10%+ annual constant currency revenue growth potential we see for our business," said Ayers.

Second Quarter Financial Performance Highlights

Companion Animal Group revenue grew 14%, or 13% on an organic basis, in the second quarter. These results were driven by 13% reported and 12% organic growth in CAG Diagnostics recurring revenues, and 35% reported and organic revenue growth in CAG Diagnostics instruments. As noted, CAG Diagnostics recurring revenue gains were supported by strong growth in reference laboratory diagnostic and consulting services and IDEXX VetLab(®) consumables. Rapid assay reported and organic revenue growth increased 7% due to higher volume and timing of promotional programs.

Water revenue grew 11%, or 12% on an organic basis, in the second quarter, driven by worldwide increases in core coliform and E.coli products, as well as an approximate 4% growth benefit from project related revenues and incremental revenues associated with the 2015 Crypto outbreak in the UK.

Livestock, Poultry and Dairy ("LPD") revenue increased 2%, or 4% on an organic basis, in the second quarter, reflecting solid growth in China and Latin America, partially offset by lower bovine revenue in Europe.

Gross profit increased 12% compared to the prior year period. Gross margin decreased from 56.3% to 55.8%, reflecting the unfavorable impact of foreign exchange rates (including 1.2% of negative gross margin impact related to the lapping of prior year hedge gains). On a constant currency basis, gross margin improved solidly driven by benefits from moderate price gains and productivity achieved in our reference laboratory and veterinary software service businesses, which offset mix impacts from higher instrument revenues.

Operating expenses increased 8% in the second quarter, in line with first quarter growth levels and relatively lower than expected, in part reflecting delays in timing for certain investments. Operating margin was 22.3% in the second quarter, up from prior year period operating margin of 21.4%, reflecting flow-through benefits from very strong second quarter revenue growth.

Keywords for this news article include: Finance and Investment, Idexx Laboratories Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Business Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
08/11 IDEXX LABORATORIES : Announces Second Quarter Results
08/10 IDEXX LABORATORIES : to Host 2016 Investor Day
08/08 IDEXX LABORATORIES : to Host 2016 Investor Day
08/04 IDEXX LABORATORIES : Releases Revolutionary Water Test to Aid in the Fight Again..
08/02 IDEXX LABORATORIES : DE Management's Discussion and Analysis of Financial Condit..
08/02 IDEXX LABORATORIES : beats Street 2Q forecasts
08/02 IDEXX LABORATORIES INC /DE : Results of Operations and Financial Condition, Fina..
08/02 IDEXX LABORATORIES : Announces Second Quarter Results
07/28IDEXX LABORATORIES, INC. : half-yearly earnings release
07/27 IDEXX LABORATORIES : Releases Revolutionary Water Test to Aid in the Fight Again..
More news
Sector news : Veterinary Medical Equipment & Supplies
12:43a ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26DJST JUDE MEDICAL : . Jude Denies Report Its Heart Devices Are Vulnerable to Cyber..
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
08/26DJST JUDE MEDICAL : . Jude Denies Report Its Heart Devices Are Vulnerable to Cyber..
More sector news : Veterinary Medical Equipment & Supplies
News from SeekingAlpha
08/04 Top Dogs (And Stocks In The Dog House) - Cramer's Mad Money (8/3/16)
08/02 IDEXX Laboratories (IDXX) Jonathan W. Ayers on Q2 2016 Results - Earnings Cal..
08/02 IDEXX Laboratories beats by $0.12, beats on revenue
08/01 Notable earnings before Tuesday?s open
07/20 Tips To Play The Earnings Season - Cramer's Mad Money (7/19/16)
Financials ($)
Sales 2016 1 771 M
EBIT 2016 340 M
Net income 2016 211 M
Debt 2016 745 M
Yield 2016 -
P/E ratio 2016 46,66
P/E ratio 2017 41,04
EV / Sales 2016 5,99x
EV / Sales 2017 5,37x
Capitalization 9 863 M
More Financials
Duration : Period :
IDEXX Laboratories, Inc. Technical Analysis Chart | IDXX | US45168D1046 | 4-Traders
Full-screen chart
Technical analysis trends IDEXX LABORATORIE...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 116 $
Spread / Average Target 4,9%
Consensus details
EPS Revisions
More Estimates Revisions
Jonathan W. Ayers Chairman, President & Chief Executive Officer
Brian P. McKeon Chief Financial Officer, Treasurer & Executive VP
Rebecca M. Henderson Independent Director
Thomas Craig Independent Director
Barry C. Johnson Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC12.58%120 679
ESSILOR INTL.-1.83%27 578
More Results